Autolus Therapeutics plc (ADR)
General ticker "AUTL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $451.4M (TTM average)
Autolus Therapeutics plc (ADR) follows the US Stock Market performance with the rate: 39.4%.
Estimated limits based on current volatility of 4.5%: low 2.28$, high 2.50$
Factors to consider:
- Total employees count: 752 (+16.2%) as of 2025
- US accounted for 79.6% of revenue in the fiscal year ended 2023-12-31
- Top business risk factors: Clinical trial delays, Regulatory and compliance, Manufacturing scale up, Market competition, Capital constraints
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.98$, 2.72$]
- 2026-12-31 to 2027-12-31 estimated range: [1.23$, 3.17$]
Financial Metrics affecting the AUTL estimates:
- Positive: with PPE of -1.7 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -59.43 <= 0.30
- Positive: Investing cash flow per share per price, % of 33.21 > -0.65
- Negative: negative Net income
- Positive: 19.10 < Shareholder equity ratio, % of 30.24 <= 42.34
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term AUTL quotes
Long-term AUTL plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1.70MM | $10.12MM | $75.39MM |
| Operating Expenses | $181.40MM | $251.55MM | $345.93MM |
| Operating Income | $-179.70MM | $-241.43MM | $-270.54MM |
| Non-Operating Income | $-28.70MM | $22.29MM | $-15.01MM |
| Interest Expense | $45.07MM | $9.29MM | $36.67MM |
| R&D Expense | $130.48MM | $138.44MM | $117.69MM |
| Income(Loss) | $-208.40MM | $-219.13MM | $-285.56MM |
| Taxes | $-0.02MM | $1.53MM | $1.97MM |
| Net Income(Loss)* | $-208.38MM | $-220.66MM | $-287.53MM |
| Stockholders Equity | $111.47MM | $427.32MM | $178.13MM |
| Inventory | $0.00MM | $4.14MM | $33.21MM |
| Assets | $375.38MM | $782.73MM | $589.07MM |
| Operating Cash Flow | $-145.59MM | $-206.27MM | $-283.57MM |
| Capital expenditure | $10.99MM | $34.82MM | $27.13MM |
| Investing Cash Flow | $-10.99MM | $-394.55MM | $158.46MM |
| Financing Cash Flow | $-0.88MM | $589.55MM | $-4.34MM |
| Earnings Per Share** | $-1.20 | $-0.86 | $-1.08 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.